GlassScriptPhysician profile
Thomas W Perron
NPI 1710179825
$1,331.50
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.51 · 2022: $59.73 · 2023: $255 · 2024: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.27 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $404.59 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $247.19 | 2023-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $179.85 | 2021-2024 | Invega Sustenna, Spravato |
| Abbvie INC. | $115.45 | 2023-2024 | |
| Axsome Therapeutics, INC. | $113.32 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.99 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $48.65 | 2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $41.10 | 2024 | Cobenfy |
| Indivior INC. | $39.45 | 2022-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $35.43 | 2023 | Quviviq |
| Alkermes, INC. | $24.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.55 | 2024 | Abilify Maintena, Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Perron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.